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Abstract
Rebound disease following cessation of disease modifying treatment (DMT) has
been reported in people with both relapsing and progressive multiple sclerosis
(pwRMS, pwPMS) questioning strict separation between these two phenotypes.
While licensed DMT is available for pwRMS to counter rebound disease, no
such option exists for pwPMS. We report on a pwPMS who developed rebound
disease, with 45 Gadolinium-enhancing lesions on T1 weighted MRI brain,
within 6 months after fingolimod 0.5 mg/day was stopped. Treatment with a
short course of subcutaneous cladribine 60 mg led to effective suppression of
inflammatory activity and partial recovery with no short-term safety issues or
adverse events.
Introduction
Fingolimod is an effective disease-modifying treatment
(DMT) for people with relapsing multiple sclerosis
(pwRMS). It has also undergone a phase III trial in people
with progressive MS (pwPMS) failing to show efficacy on
the primary endpoint.1 A key mechanism of action of fin-
golimod is believed to be sequestering of pathogenic lym-
phocytes in lymph nodes2 thereby preventing entry into the
central nervous system (CNS). When treatment is stopped
lymphocyte levels usually return to normal within
4–8 weeks. The resulting release of lymphocytes back into
the blood circulation may cause “rebound” disease, defined
as a degree of disease activity significantly exceeding pre-
DMT activity.3,4 We report a case of rebound disease after
fingolimod cessation in a pwPMS, who was successfully
treated with Cladribine as an off-label “rescue” therapy.
Case report
Written informed consent was obtained from the patient
for her clinical information and MRI to be published.
At the age of 28, a woman of Afro-Caribbean origin
first noticed weakness of her right leg. Neurological signs
on examination were indicative of an upper motor neu-
ron syndrome, which steadily deteriorated henceforth.
Thorough diagnostic work-up including MRI head and
spinal cord, and assessment of her cerebro-spinal fluid,
revealed her lower limb paresis to be the first manifesta-
tion of primary progressive MS (PPMS).
Five years after disease onset she was enrolled in the
phase III trial of fingolimod 0.5 mg/day in PPMS
(INFORMS).1 She had never been treated with a DMT
before.
Examination at baseline of the trial revealed bilateral
internuclear ophthalmoplegia and right-sided hemiparesis
limiting her walking range to 100–200 m. Her expanded
disability status scale (EDSS) score was 5.5. MRI brain at
screening showed 57 demyelinating lesions on T2
weighted scans. In the cervical spinal cord two lesions
were detected (Figure). Two of the brain lesions showed
Gadolinium-enhancement (Gd+) (Fig. 1A). Subsequent
annual MRI head and cervical spine studies during
INFORMS did not reveal any significant change in the
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number or volume of lesions, and no Gd+ lesions. Mild
brain atrophy was noted (Fig. 1A and B). Unblinding
after completion of INFORMS confirmed the patient had
been randomized to fingolimod, of which she took the
last dose during the open-label extension phase in
December 2014. Over the course of INFORMS, a total
duration of 3 years and 7 months including the extension
phase, her EDSS deteriorated from 5.5 to 6.5 (Fig. 2A–E).
Six months after taking the last capsule of fingolimod,
she presented to our clinic with significant exacerbation
over the course of 1 week of her right-sided hemiparesis.
She was unable to walk and had a new thoracic sensory
level. On examination power of hip flexion on the left
was MRC grade 2-3/5, on the right 1/5. Knee flexion was
MRC 3/5 on the left and 0/5 on the right. Upper limb
weakness had deteriorated on the right with MRC grades
2/5 distally and 4-/5 proximally. There was a new sensory
level for touch and pain from T6 downwards bilaterally.
Her EDSS was 8 (Fig. 2A). MRI head acquired within
1 week of deterioration showed 48 new T2 lesions, of
which 45 were Gd+ on T1 (Fig. 1C; Figure S1).
Given the significant clinical and MRI-detected disease
activity, we offered treatment using Cladribine 60 mg s.c.
over 5 weeks.5 On follow-up 3 months after treatment
initiation her EDSS had improved to 7, and MRI head at
this time did not show any evidence of new T2 lesions
and no Gd+ lesions (Fig. 1D).
Discussion
Irrespective of the disease course, withdrawal of DMT in
MS poses the risk of resuming disease activity including
rebound.3,6,7 Whilst progressive MS, particularly PPMS is
often characterized by a relative quiescence in terms of
lesion activity detected on MRI,8 there are many excep-
tions from this rule, and PPMS should therefore be con-
sidered as one end of the spectrum of MS presentations
(the other being relapsing MS with a high relapse rate),
rather than an altogether distinct subtype.8 This view is
supported by the revised classification of MS into active
and non-active (1) relapsing and (2) progressive disease,
and a lesser emphasis on “primary” versus “secondary”
progression.9 Against this backdrop, it makes evident
sense to include clinical semiology as well as MRI appear-
ance when deciding about the likelihood of response to
DMT, be it licensed or off-label.
Two previously reported patients6 share similarities
with our case. They both had PPMS, participated in
INFORMS, and developed relapses and MRI-documented
disease activity 3–6 months after treatment cessation. Our
case was characterized by steady deterioration, without
any clinical relapses and two Gd+ lesions at entry into the
INFORMS trial. Significant clinical deterioration resem-
bling a severe relapse after stopping fingolimod, and asso-
ciated MRI activity, suggested two things, (1) that
Figure 1. (A) Baseline MRI taken before entrance to INFORMS study. (B) Last MRI taken at the end of INFORMS study. (C) MRI taken 6 months
after suspending Fingolimod and during the clinical relapse. (D) MRI taken 3 months after receiving treatment with Cladribine.
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Figure 2. Neurological status during and after the INFORMS study and lymphocyte counts. (A) Expanded disability status scale (EDSS) pre- and
post-INFORMS, and after relapse. (B) Timed 25-Foot walk (T25-FW) during INFORMS study. (C) Hand function during INFORMS assessed with
9-Hole Peg Test (9-HPT). (D) EQ-5D score during INFORMS study. (E) MS walking scale during INFORMS study. (F) Lymphocyte counts during
INFORMS, pre- and post-Cladribine.
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fingolimod effectively suppressed disease activity over the
course of the study, and (2) that DMT, despite the lack
of any licensed options, would have a reasonable likeli-
hood of success.
Given the lack of licensed DMT we offered Cladribine,
a purine analogue and effective B and T lymphocyte
depleting drug for pwRMS,10 as a convenient and safe
option. In support of this decision we considered the evi-
dence for Cladribine being effective in pwMS from previ-
ous phase III trials,10,11 and our recent work
demonstrating there is no short-term increase in the risk
of cancer with Cladribine compared to licensed DMT.12
Moreover, earlier phase II trials providing evidence of
efficacy in pwPMS13–15 the convenience of an induction
treatment, and the availability of Cladribine as an off-
label drug for people with hairy cell leukemia all played a
role in this decision. Finally, Cladribine penetrates into
the CNS,16 which may be advantageous in pwPMS
through treatment effect on meningeal B and T lympho-
cyte clusters described in post mortem samples of
pwPMS.17
Evidence suggests Rituximab is effective in young
pwPMS with active MRI scans. In the OLYMPUS trial of
PPMS, Rituximab slowed disease deterioration in patients
less than 51 years of age, and with Gd+ lesions, suggesting
a subgroup of pwPMS may well benefit from B cell deple-
tion.18 Rituximab has also been offered recently as an off-
label rescue therapy in pwRRMS following rebound activ-
ity after cessation of fingolimod.3 Moreover, the human-
ised anti-CD20 antibody Ocrelizumab has been
successfully tested in a phase III trial of patients with
PPMS.19 However, Rituximab remains relatively expen-
sive, and in our healthcare environment (NHS) would
have required an individual funding application with (1)
potential for delay and (2) likely rejection, based on
recent experience. Further alternative DMTs, such as
Mitoxantrone and Cyclophosphamide (both off-label in
the UK), carry evidently more significant risks including
malignancy and cardiotoxicity.20,21
We selected Cladribine for the following reasons: (1)
class I evidence of efficacy of the active compound in
people with relapsing MS10,15,22; (2) selective lymphocyte
mechanism of action not requiring cell-proliferation and
notably B cell targeting potential that appears to be asso-
ciated with effective control of active MS23,24; (3) CNS
penetration for peripheral and CNS immune cell inactiva-
tion and modulation16,23; (4) safety comparable or better
than similarly effective, current treatments12; (5) known
relative safety in people with advanced MS15; (6) induc-
tion therapy potential requiring only short courses of
treatment10 with rapid elimination from the body poten-
tially allowing additional use of neuroprotection and
symptomatic treatments without complications due to
drug-drug interactions23; and importantly, (7) conve-
nience for the patient with easy and rapid administration
during brief hospital visits to our day case unit, and few
monitoring needs compared to some of the current
DMT. This will limit travel requirements for someone
restricted to a wheelchair. We felt this list of advantages
outweighs the use of alternatives, such as cyclophos-
phamide, that lack the weight of evidence of efficacy in
phase III studies whilst evidently having significantly
more side-effects.25 Indeed based on the above issues,
parenteral cladribine may have some practical and clinical
advantages over currently licensed DMT and offers addi-
tional value via cost-effectiveness, due to its availability as
a generic product (for hairy cell leukemia). The low price
is an important factor for pwPMS to gaining access to
DMT. In our healthcare system (NHS) it is not worth
even considering treatment with licensed DMT a patient
who does not fulfill the NHS criteria for treatment.
Our dosing scheme for Cladribine took into account
comments by the European Medicines Agency in their
withdrawal assessment of Cladribine tablets in 2010/11
regarding the risk of severe lymphopenia (http://www.e
ma.europa.eu/docs/en_GB/document_library/Application_
withdrawal_assessment_report/2011/03/WC500104393.pdf
). Based on 100% bioavailability of Cladribine s.c. (versus
42% or the oral prodrug) 60 mg Cladribine/year in an
individual weighing less than 90 kg resembles bio-equiva-
lence with the oral 3.5 mg/kg dose used in the pivotal
CLARITY MS study.10 Cladribine 10 mg s.c. was given on
days 1, 2 and 3 in week one.11 We then checked the total
lymphocyte count in week 4 (Fig. 2F). After confirming
the total lymphocyte count remained within normal limits
we administered further doses Cladribine of 10 mg s.c. on
days 1, 2 and 3 in week 5. No adverse effects were
observed. Clinically, the patient improved to EDSS 7, with
no disease activity detected on follow-up MRI. A second
treatment cycle is planned 11 months after the first.
In conclusion, we report the case of a pwPMS who
developed rebound disease after fingolimod cessation and
partially recovered following Cladribine administration.
Successful treatment in this case should encourage studies
to more definitely investigate the effectiveness of
immunosuppressive DMT in pwPMS. Based on its safety,
convenience, and unique pharmacokinetics including
CNS penetration Cladribine is a promising candidate
DMT for pwPM.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Figure S1. (A) Baseline MRI of spinal cord showed T2
lesions before entrance to INFORMS study; no
gadolinium-enhancement study was performed. (B)
Spinal cord MRI acquired within 1 week of deterioration
showing T2 lesions and Gd
+ on T1.
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